Development of a Novel In-Situ Telomere Length Qualification System to Address Suitability of Telomerase Inhibitor Therapy to Breast Cancer
Abstract
The ability to predetermine therapeutic intervention times following tumor resection would be invaluable to patient well being and clinical resources. We sought to determine if we could establish a methodology where in vivo tumor telomere length could be established using in situ hybridisation as a quantitative tool. This technique would require development, validation, and application to a model system. A three dimensional technique to measure telomere length was established. This technique was applied to breast cancer derived tumor cell lines thereby establishing technique, methodology, and validity. In vivo application was established using both a readily available tissue source and tumors derived from tumorigenic breast cancer cell lines. Combining the approach to breast cancer cell lines we were then able to approximate at required times of telomerase inhibition before driving the cells into telomere-driven replicative senescence. This technique represents an important development in the ability to measure telomere length in vivo and ultimately could become appropriate for clinical application.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2004
- Accession Number
- ADA425971
Entities
People
- Nicholas R. Forsyth
Organizations
- University of Texas at Dallas